Martin Jonathan W, Asher Brian J, Beesoon Sanjay, Benskin Jonathan P, Ross Matthew S
Division of Analytical and Environmental Toxicology, Department of Laboratory Medicine and Pathology, University of Alberta, 10-102 Clinical Sciences Building, Edmonton, Alberta, CanadaT6G 2G3.
J Environ Monit. 2010 Nov;12(11):1979-2004. doi: 10.1039/c0em00295j. Epub 2010 Oct 13.
The extent to which perfluorooctanesulfonate precursors (PreFOS) play a role in human or environmental exposure to perfluorooctanesulfonate (PFOS) is not well characterized. The diversity of manufactured PreFOS and its degradation products (e.g. C(8)F(17)SO(2)R and C(8)F(17)SO(2)NR'R'', where R is H or F, and R' and R'' are various) has made it difficult to track their fate. Temporal trends of PFOS in both humans and wildlife are discrepant, thus it is difficult to predict future exposure, and hypotheses about the role of PreFOS have been raised. Although abiotic degradation of commercially important PreFOS materials requires further research, current data suggest that the yield of PFOS is negligible or minor. On the other hand, in vivo biotransformation of PreFOS yields PFOS as the major metabolite, and >32% yields have been observed. In Canadians, exposure to PreFOS was equivalent or greater than direct PFOS exposure prior to 2002. In most ocean water, PFOS is dominant to PreFOS, but in the oceans east of Greenland there may be more PreFOS than PFOS, consistent with the fact that whales and humans in this region also show evidence of substantial PreFOS exposure. Quantitative assessments of PFOS body-burdens coming from PreFOS are complicated by the fact that PreFOS partitions to the cellular fraction of blood, thus biomonitoring in serum under predicts PreFOS relative to PFOS. Many unknowns exist that prevent accurate modelling, thus analytical methods that can distinguish directly manufactured PFOS, from PFOS that has been biotransformed from PreFOS, should be applied in future human and environmental monitoring. Two new source tracking principles are presented and applied to human serum.
全氟辛烷磺酸前体(PreFOS)在人类或环境接触全氟辛烷磺酸(PFOS)中所起的作用尚未得到充分表征。PreFOS及其降解产物(例如C(8)F(17)SO(2)R和C(8)F(17)SO(2)NR'R'',其中R为H或F,R'和R''各不相同)种类繁多,这使得追踪它们的去向变得困难。人类和野生动物体内PFOS的时间趋势存在差异,因此难以预测未来的接触情况,关于PreFOS作用的假设也随之产生。尽管商业上重要的PreFOS材料的非生物降解还需要进一步研究,但目前的数据表明PFOS的产量可以忽略不计或很少。另一方面,PreFOS在体内的生物转化会产生PFOS作为主要代谢产物,并且已观察到产率>32%。在加拿大人中,2002年之前PreFOS的接触量与直接PFOS接触量相当或更高。在大多数海水中,PFOS比PreFOS占主导地位,但在格陵兰岛以东的海洋中,PreFOS可能比PFOS更多,这与该地区鲸鱼和人类也有大量PreFOS接触的证据一致。由于PreFOS会分配到血液的细胞部分,因此对来自PreFOS的PFOS体内负荷进行定量评估很复杂,相对于PFOS,血清中的生物监测会低估PreFOS。存在许多未知因素阻碍了准确建模,因此在未来的人类和环境监测中应应用能够区分直接制造的PFOS和由PreFOS生物转化而来的PFOS的分析方法。本文提出了两种新的来源追踪原则并将其应用于人类血清。